Evidence mapPaperPMID 41408309Full record

ArticleJournal of translational medicine2025

CEBPD-mediated SGPP2 upregulation via PERK/ER stress in endothelial cells disrupts S1P homeostasis and impairs angiogenesis in chronic endometritis.

Yanjun Wang, Xiaoyan Chen, Guanying You, Shuyi Yu, Cong Chen, Ruochun Lian, Lianghui Diao, Yuye Li, Tailang Yin

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yanjun WangReproductive Medicine Center, Renmin Hospital of Wuhan University, No. 99, Zhang Zhidong Road, Wuchang District, Wuhan, Hubei Province, 430060, China.
Xiaoyan ChenShenzhen Key Laboratory of Reproductive Immunology for Peri- implantation, Shenzhen Zhongshan Institute for Reproductive Medicine and Genetics, Shenzhen Zhongshan Obstetrics & Gynecology Hospital (formerly Shenzhen Zhongshan Urology Hospital), No. 1001, Fuqiang Road, Futian District, Shenzhen, Guangdong Province, 518045, China.
Guanying YouShenzhen Key Laboratory of Reproductive Immunology for Peri- implantation, Shenzhen Zhongshan Institute for Reproductive Medicine and Genetics, Shenzhen Zhongshan Obstetrics & Gynecology Hospital (formerly Shenzhen Zhongshan Urology Hospital), No. 1001, Fuqiang Road, Futian District, Shenzhen, Guangdong Province, 518045, China.
Shuyi YuShenzhen Key Laboratory of Reproductive Immunology for Peri- implantation, Shenzhen Zhongshan Institute for Reproductive Medicine and Genetics, Shenzhen Zhongshan Obstetrics & Gynecology Hospital (formerly Shenzhen Zhongshan Urology Hospital), No. 1001, Fuqiang Road, Futian District, Shenzhen, Guangdong Province, 518045, China.
Cong ChenShenzhen Key Laboratory of Reproductive Immunology for Peri- implantation, Shenzhen Zhongshan Institute for Reproductive Medicine and Genetics, Shenzhen Zhongshan Obstetrics & Gynecology Hospital (formerly Shenzhen Zhongshan Urology Hospital), No. 1001, Fuqiang Road, Futian District, Shenzhen, Guangdong Province, 518045, China.
Ruochun LianShenzhen Key Laboratory of Reproductive Immunology for Peri- implantation, Shenzhen Zhongshan Institute for Reproductive Medicine and Genetics, Shenzhen Zhongshan Obstetrics & Gynecology Hospital (formerly Shenzhen Zhongshan Urology Hospital), No. 1001, Fuqiang Road, Futian District, Shenzhen, Guangdong Province, 518045, China.
Lianghui DiaoShenzhen Key Laboratory of Reproductive Immunology for Peri- implantation, Shenzhen Zhongshan Institute for Reproductive Medicine and Genetics, Shenzhen Zhongshan Obstetrics & Gynecology Hospital (formerly Shenzhen Zhongshan Urology Hospital), No. 1001, Fuqiang Road, Futian District, Shenzhen, Guangdong Province, 518045, China.
Yuye LiShenzhen Key Laboratory of Reproductive Immunology for Peri- implantation, Shenzhen Zhongshan Institute for Reproductive Medicine and Genetics, Shenzhen Zhongshan Obstetrics & Gynecology Hospital (formerly Shenzhen Zhongshan Urology Hospital), No. 1001, Fuqiang Road, Futian District, Shenzhen, Guangdong Province, 518045, China. liyuye519@163.com.
Tailang YinReproductive Medicine Center, Renmin Hospital of Wuhan University, No. 99, Zhang Zhidong Road, Wuchang District, Wuhan, Hubei Province, 430060, China. reproductive@whu.edu.cn.

Funding

National Natural Science Foundation of China Grant 82571923Shenzhen Fundamental Research Program JCYJ20220530172817039, JCYJ20240813152902004
6 · The paper itself

Abstract

backgroundChronic endometritis (CE) is a persistent inflammatory condition associated with adverse pregnancy outcomes. Although impaired endometrial angiogenesis is thought to contribute to its pathogenesis, the underlying molecular mechanisms remain incompletely understood. This study aimed to investigate whether sphingolipid metabolism plays a role in the vascular dysfunction of CE patients.

methodsEndometrial samples from control and CE patients were assessed for angiogenesis using immunohistochemistry. Sequencing data of endometrial tissues indicated dysregulation of sphingolipid metabolism in CE patients. ELISA revealed decreased levels of sphingosine-1-phosphate (S1P) in the endometrium of CE patients and in lipopolysaccharide (LPS)-treated human umbilical vein endothelial cells (HUVECs). Functional assays including tube formation, wound healing, and transwell invasion were performed to evaluate the effects of LPS and S1P on HUVECs. Western blotting was used to explore the signaling pathways through which S1P influences HUVECs function after LPS stimulation. RT-qPCR and Western blot analyses further suggested that the reduction in S1P under inflammatory conditions may be attributable to upregulation of sphingosine-1-phosphate phosphatase 2 (SGPP2). Chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays were employed to detect CEBPD binding to the SGPP2 promoter, and immunofluorescence was used to assess nuclear localization of relevant factors. Knockout experiments were conducted to validate the relationship among CEBPD, SGPP2, and endoplasmic reticulum (ER) stress. Finally, the effect of S1P on pregnancy outcomes was evaluated in a CE mouse model.

resultsMicrovessel density (MVD) and S1P levels were decreased in both CE patients and the CE mouse model. In HUVECs, LPS suppressed tube formation, migration, and invasion; these effects were reversed by exogenous S1P via the S1PR1-STAT3-VEGFA pathway. SGPP2, an S1P-degrading enzyme, was upregulated in CE endometrial tissues and in LPS-stimulated HUVECs. Mechanistically, the transcription factor CEBPD was shown to directly bind the SGPP2 promoter and promote its expression, a process dependent on PERK-eIF2α-mediated ER stress. In the mouse model, intrauterine administration of S1P attenuated endometrial inflammation, improved angiogenesis, and significantly reduced embryo resorption rates.

conclusionsOur findings delineate a novel pathway linking inflammatory stress to aberrant angiogenesis in endometrium, in which ER stress-driven CEBPD activation transcriptionally upregulates SGPP2, creating a molecular nexus between inflammation and sphingolipid metabolism. This S1P signaling deficit compromises a critical angiogenic pathway necessary for vascular remodeling, which in turn disrupts endometrial receptivity and contributes to CE-associated reproductive failures.

Indexed as

eIF-2 KinaseEndometritisEndoplasmic Reticulum StressHomeostasisLysophospholipidsNeovascularization, PathologicPhosphoric Monoester HydrolasesSphingosineUp-RegulationAngiogenesisAnimalsChronic DiseaseEndometriumFemaleHumansHuman Umbilical Vein Endothelial CellseIF-2 KinaseLipopolysaccharidesLysophospholipidsPhosphoric Monoester HydrolasesSphingosinesphingosine 1-phosphateAngiogenesisChronic endometritisEndoplasmic reticulum stressSGPP2Sphingosine-1-phosphate (S1P)

Identifiers

PMID41408309
PMCPMC12822190

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.